Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice
Authors:
- 26 April 2016
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 45 (6) , 456-460
Abstract
Objectives: To assess and compare the long-term drug survival (time to drug discontinuation) of biological agents (BA) in patients with rheumatoid arthritis (RA) in clinical practice. Factors associated with discontinuation of BAs were also investigated. Method: We conducted an observational longitudinal study of RA patients taking BAs from 1999 to 2013. The primary endpoint was BA discontinuation due to: adverse drug reactions (ADRs), inefficacy, and other causes. Incidence rates of discontinuation (IRs) per 100 patient-years were estimated using survival techniques. Comparisons between BA discontinuation rates and other associated factors were made using Cox regression models. Results: We included 851 courses of BA therapy (1869 patient-years). Adalimumab (33%) was the BA most frequently used, followed by etanercept (24.4%), infliximab, and rituximab. Treatment was suspended in 558 cases [IR 29.8, 95% confidence interval (CI) 27–32]. In the first year of therapy 68% continued on BAs, and after 10 years the retention rate did not exceed 10%. The IR due to inefficacy was 12.1 (95% CI 10.6–13.8) and the IR of ADRs was 13.6 (95% CI 12–15). The unadjusted IR was higher for rituximab than for tumour necrosis factor (TNF) antagonists. In multivariate analysis, infliximab was the BA with the highest risk of discontinuation, compared to adalimumab. Calendar period, taking subsequent courses of BAs, concomitant therapy, and specific comorbidities were also independent factors associated with discontinuation. Conclusions: After several years of BA treatment in clinical practice, the survival rate was low, mainly as a result of ADRs and inefficacy. We also found differences between the discontinuation rates of BAs and other clinical factors that modify their survival.Keywords
Funding Information
- Pfizer Foundation (WS2387261)
This publication has 13 references indexed in Scilit:
- Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximabAnnals of the Rheumatic Diseases, 2015
- Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practiceJoint Bone Spine, 2014
- Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug RegistersInternational Journal of Rheumatology, 2013
- Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring registerRheumatology, 2010
- Altered expression of microRNA‐203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activationArthritis & Rheumatism, 2010
- Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registryArthritis & Rheumatism, 2009
- TNF‐α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical PracticeAnnals of the New York Academy of Sciences, 2009
- Changing Patterns of Tumor Necrosis Factor Inhibitor Use in 9074 Patients with Rheumatoid ArthritisThe Journal of Rheumatology, 2009
- The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practiceAnnals of the Rheumatic Diseases, 2007
- Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2006